Cargando…
Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol
BACKGROUND: Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388271/ https://www.ncbi.nlm.nih.gov/pubmed/34433596 http://dx.doi.org/10.1136/bmjopen-2020-048168 |
_version_ | 1783742606817099776 |
---|---|
author | Gastens, Viktoria Del Giovane, Cinzia Anker, Daniela Feller, Martin Syrogiannouli, Lamprini Schwab, Nathalie Bauer, Douglas C Rodondi, Nicolas Chiolero, Arnaud |
author_facet | Gastens, Viktoria Del Giovane, Cinzia Anker, Daniela Feller, Martin Syrogiannouli, Lamprini Schwab, Nathalie Bauer, Douglas C Rodondi, Nicolas Chiolero, Arnaud |
author_sort | Gastens, Viktoria |
collection | PubMed |
description | BACKGROUND: Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to the estimated LE, there is no tool to estimate LE in this specific population. Our objective is therefore to develop an LE estimator for older multimorbid adults by transforming a mortality prognostic index, which will be developed and internally validated in a prospective cohort. METHODS AND ANALYSIS: We will analyse data of the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People cohort study in Bern, Switzerland. 822 participants were included at hospitalisation with age of 70 years or older, multimorbidity (three or more chronic medical conditions) and polypharmacy (use of five drugs or more for >30 days). All-cause mortality will be assessed during 3 years of follow-up. We will apply a flexible parametric survival model with backward stepwise selection to identify the mortality risk predictors. The model will be internally validated using bootstrapping techniques. We will derive a point-based risk score from the regression coefficients. We will transform the 3-year mortality prognostic index into an LE estimator using the Gompertz survival function. We will perform a qualitative assessment of the clinical usability of the LE estimator and its application. We will conduct the development and validation of the mortality prognostic index following the Prognosis Research Strategy (PROGRESS) framework and report it following the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement. ETHICS AND DISSEMINATION: Written informed consent by patients themselves or, in the case of cognitive impairment, by a legal representative, was required before enrolment. The local ethics committee (Kantonale Ethikkommission Bern) has approved the study. We plan to publish the results in peer-reviewed journals and present them at national and international conferences. |
format | Online Article Text |
id | pubmed-8388271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-83882712021-09-14 Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol Gastens, Viktoria Del Giovane, Cinzia Anker, Daniela Feller, Martin Syrogiannouli, Lamprini Schwab, Nathalie Bauer, Douglas C Rodondi, Nicolas Chiolero, Arnaud BMJ Open Epidemiology BACKGROUND: Older multimorbid adults have a high risk of mortality and a short life expectancy (LE). Providing high-value care and avoiding care overuse, including of preventive care, is a serious challenge among multimorbid patients. While guidelines recommend to tailor preventive care according to the estimated LE, there is no tool to estimate LE in this specific population. Our objective is therefore to develop an LE estimator for older multimorbid adults by transforming a mortality prognostic index, which will be developed and internally validated in a prospective cohort. METHODS AND ANALYSIS: We will analyse data of the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People cohort study in Bern, Switzerland. 822 participants were included at hospitalisation with age of 70 years or older, multimorbidity (three or more chronic medical conditions) and polypharmacy (use of five drugs or more for >30 days). All-cause mortality will be assessed during 3 years of follow-up. We will apply a flexible parametric survival model with backward stepwise selection to identify the mortality risk predictors. The model will be internally validated using bootstrapping techniques. We will derive a point-based risk score from the regression coefficients. We will transform the 3-year mortality prognostic index into an LE estimator using the Gompertz survival function. We will perform a qualitative assessment of the clinical usability of the LE estimator and its application. We will conduct the development and validation of the mortality prognostic index following the Prognosis Research Strategy (PROGRESS) framework and report it following the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement. ETHICS AND DISSEMINATION: Written informed consent by patients themselves or, in the case of cognitive impairment, by a legal representative, was required before enrolment. The local ethics committee (Kantonale Ethikkommission Bern) has approved the study. We plan to publish the results in peer-reviewed journals and present them at national and international conferences. BMJ Publishing Group 2021-08-25 /pmc/articles/PMC8388271/ /pubmed/34433596 http://dx.doi.org/10.1136/bmjopen-2020-048168 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Epidemiology Gastens, Viktoria Del Giovane, Cinzia Anker, Daniela Feller, Martin Syrogiannouli, Lamprini Schwab, Nathalie Bauer, Douglas C Rodondi, Nicolas Chiolero, Arnaud Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
title | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
title_full | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
title_fullStr | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
title_full_unstemmed | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
title_short | Development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
title_sort | development and validation of a life expectancy estimator for multimorbid older adults: a cohort study protocol |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388271/ https://www.ncbi.nlm.nih.gov/pubmed/34433596 http://dx.doi.org/10.1136/bmjopen-2020-048168 |
work_keys_str_mv | AT gastensviktoria developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT delgiovanecinzia developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT ankerdaniela developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT fellermartin developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT syrogiannoulilamprini developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT schwabnathalie developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT bauerdouglasc developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT rodondinicolas developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol AT chioleroarnaud developmentandvalidationofalifeexpectancyestimatorformultimorbidolderadultsacohortstudyprotocol |